Vanna Dest on Cardiac Toxicity Following Radiation Therapy
Vanna Dest, MSN, APRN-BC, AOCN, from the Yale-New Haven Hospital, discusses cardiac toxicity in patients receiving radiation therapy.
Vanna Dest, MSN, APRN-BC, AOCN, Oncology Nurse Practitioner/Manager, Oncology APP, Yale-New Haven Hospital, discusses cardiac toxicity in patients receiving radiation therapy.
Cardiac toxicity is a big problem following radiation therapy, Dest says, particularly in patients with Hodgkin's lymphoma, left-sided breast cancer, and lung cancer. Age as well as combined modalities play a role in cardiac toxicity, as many patients are being treated with chemotherapy as well as radiation therapy.
Dest says that specific cardiac toxicities that need to be monitored include cardiomyopathy, coronary artery disease, valve changes, and conduction problems.
ERBT Before Ra-223 May Not Increase Hematological Toxicity in mCRPC
January 26th 2024Patients with metastatic castration-resistant prostate cancer who were previously treated with external beam radiation therapy before radium-223 did not experience an increase in hematological toxicity compared with the overall population.
